US20070243632A1 - Methods for measuring platelet reactivity of patients that have received drug eluting stents - Google Patents

Methods for measuring platelet reactivity of patients that have received drug eluting stents Download PDF

Info

Publication number
US20070243632A1
US20070243632A1 US11/742,684 US74268407A US2007243632A1 US 20070243632 A1 US20070243632 A1 US 20070243632A1 US 74268407 A US74268407 A US 74268407A US 2007243632 A1 US2007243632 A1 US 2007243632A1
Authority
US
United States
Prior art keywords
platelet
patient
agglutination
reactivity
clopidogrel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/742,684
Other languages
English (en)
Inventor
Barry Coller
Dennis Durbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accumetrics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/886,155 external-priority patent/US7790362B2/en
Priority to US11/742,684 priority Critical patent/US20070243632A1/en
Application filed by Individual filed Critical Individual
Assigned to ACCUMETRICS, INC. reassignment ACCUMETRICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DURBIN, DENNIS, COLLER, BARRY S.
Publication of US20070243632A1 publication Critical patent/US20070243632A1/en
Priority to KR1020097024975A priority patent/KR20100017510A/ko
Priority to PCT/US2008/062297 priority patent/WO2008137600A1/en
Priority to US12/598,581 priority patent/US9506938B2/en
Priority to CN200880022878A priority patent/CN101688871A/zh
Priority to EP08754988A priority patent/EP2145192A1/en
Priority to JP2010506656A priority patent/JP5687055B2/ja
Priority to US12/943,413 priority patent/US9341637B2/en
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK INTELLECTUAL PROPERTY SECURITY AGREEMENT (REVOLVING LOAN) Assignors: ACCUMETRICS, INC.
Assigned to SILICON VALLEY BANK, HORIZON TECHNOLOGY FINANCE CORPORATION reassignment SILICON VALLEY BANK INTELLECTUAL PROPERTY SECURITY AGREEMENT (TERM LOAN) Assignors: ACCUMETRICS, INC.
Assigned to ACCUMETRICS, INC. reassignment ACCUMETRICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: SILICON VALLEY BANK
Assigned to ACCUMETRICS, INC. reassignment ACCUMETRICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: HORIZON TECHNOLOGY FINANCE CORPORATION, SILICON VALLEY BANK
Assigned to COMERICA BANK reassignment COMERICA BANK INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: ACCUMETRICS, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Definitions

  • This invention relates to the field of diagnostic assays, and in particular to methods for measuring platelet reactivity of patients that have received drug-eluting stents (DES).
  • DES drug-eluting stents
  • platelets The role of platelets in mammalian physiology is extraordinarily diverse, but their primary role is in promoting hemostasis. In many situations, an evaluation of the ability of blood to clot is desired, a parameter that is frequently controlled by the ability of platelets to adhere and/or aggregate. Of interest, therefore, is the assessment of the adhesive functions of platelets. For example, questions of interest include whether to administer drugs that will block, or promote, clot formation, or whether to detect deficiencies in platelet function prior to surgical procedures. Also of interest is evaluating the effectiveness of a platelet inhibitor that is being tested as a new drug or is being used as approved clinical treatment in a patient.
  • Platelets are known to aggregate under a variety of conditions and in the presence of a number of different reagents. Platelet aggregation is a term used to describe the binding of platelets to one another. Platelet aggregation in vitro depends upon the ability of platelets to bind fibrinogen to their surfaces after activation by an aggregation-inducing agent such as ADP or collagen.
  • Platelets play a critical role in the maintenance of normal hemostasis. When exposed to a damaged blood vessel, platelets will adhere to exposed sub-endothelial matrix. Following the initial adhesion, various factors released or produced at the site of injury such as thrombin, ADP and collagen activate the platelets. Once platelets are activated, a conformational change occurs in the platelet glycoprotein GPIIb/IIIa receptor, allowing it to bind fibrinogen and/or von Willebrand factor.
  • In vitro platelet aggregometry is the laboratory method used to assess the in vivo ability of platelets to form the aggregates leading to a primary hemostatic plug. In this technique an aggregating agent such as ADP or collagen is added to whole blood or platelet-rich plasma and aggregation of platelets monitored. Platelet aggregometry is a diagnostic tool that can aide in patient diagnosis and selection of therapy. Current assays to measure platelet aggregation are expensive, time-consuming, cumbersome, and generally not suitable for a clinical environment.
  • a rapid platelet function assay has recently been developed and is described in U.S. Pat. No. 5,763,199 (Coller).
  • the assay determines glycoprotein (GP)IIb/IIIa receptor blockade in whole blood.
  • Agglutination of small polymeric beads coated with a GPIIb/IIIa ligand such as fibrinogen results when the beads are contacted with whole blood containing platelets with activated GPIIb/IIIa receptors that are not blocked.
  • Failure to agglutinate indicates either failure of the GPIIb/IIIa receptors to become activated and/or blockade of the GPIIb/IIIa receptors.
  • the addition of a thrombin receptor activator results in an assay that is rapid and convenient enough to be performed at the bedside and that results in agglutination of the small polymeric beads within a convenient, known period of time if the GPIIb/IIIa receptors are not blocked.
  • the assay includes the ability to transfer blood to be tested from a collection container to an assay device without opening the collection container. This platelet aggregation assay can be conducted at the same time as the activated clotting time (ACT), which is performed to assess the adequacy of heparinization.
  • ACT activated clotting time
  • Platelet aggregation plays a key role in the pathogenesis of thrombosis and acute coronary artery disease. Evidence suggests that significant platelet function variability exists in the response to various antiplatelet agents. It has also been demonstrated that an inter-individual variability in platelet aggregation exists when P2Y12 antagonists such as clopidogrel are used for treatment of patients to achieve an anti-aggregation effect.
  • Clopidogrel and ticlopidine are thienopyridine derivatives that inhibit platelet aggregation. They are believed to inhibit the binding of adenosine-5-diphosphate (ADP) to one of its receptors, the P2Y12 receptor.
  • ADP adenosine-5-diphosphate
  • the pharmacological activity of clopidogrel is very similar to the pharmacological activity of ticlopidine.
  • clopidogrel has been shown to have fewer side-effects than ticlopidine. Based on mounting evidence of the efficacy of clopidogrel in thrombotic disease, the use of clopidogrel and other P2Y12 antagonists are likely to increase significantly.
  • ADP activates at least two different receptors (P2Y1 and P2Y12 and perhaps P2X1), it has the potential for lower specificity and background noise.
  • Collagen is another choice.
  • collagen is highly variable due its quaternary structure, which dramatically affects it ability to activate platelets and due to the fact it is derived from biological tissue and sensitive to minor changes in temperature and pH.
  • Neither collagen nor ADP provide specificity to the P2Y12 receptor and therefore by themselves are not the optimal choice for the determination of the effects of P2Y12 inhibitors.
  • concentration of these two agonists has significant effect on the degree of inhibition to P2Y12 antagonists that is measured.
  • Prostaglandins belong to a ubiquitous class of chemicals known as eicosanoids. They are found in virtually every tissue in the body and have a very wide spectrum of biological activities. Eicosanoids are derivatives of arachidonic acid, a polyunsaturated fatty acid. The term eicosanoids includes the family of prostaglandins (PGs), prostacyclin, thromboxanes, and leukotrienes. The PGs are divided in different families depending on their structure, each designated by a letter (A, E, F, G, H, or 1). In addition to this letter, each individual prostaglandin carries a digit that indicates the number of double bonds in its fatty acid side chain.
  • PGE1 prostaglandin E1
  • PGE1 belongs to the E family and has only one double bond in its side chain.
  • PGs plays an important role in platelet aggregation and hemostasis (blood clotting) and typically have a marked vasodilator effect.
  • PGE1 is the theoretical cyclooxygenase metabolite of dihomo- ⁇ -linolenic acid (DGLA), but it is virtually undetectable in the plasma of normal humans or other animals. Its pharmacology includes vasodilation, hypotension, and anti-platelet activities. PGE1 has been shown to inhibit platelet aggregation by increasing cyclic adenosine monophosphate (CAMP) concentrations within platelets. A number of groups have shown that the ICS50 of PGE1 for the inhibition of ADP-induced human platelet aggregation is around 40 nM.
  • CAMP cyclic adenosine monophosphate
  • Platelet reactivity studies have demonstrated a wide inter-individual variability in the inhibitory response to clopidogrel. Retrospective and small prospective studies have demonstrated an association between a poor response to clopidogrel and clinical events after percutaneous coronary intervention (PCI). Separate from the reduction in aggregation caused by clopidogrel as judged by the percentage reduction in response to ADP, the absolute value of post-clopidogrel platelet aggregation (i.e., post-treatment reactivity), may be an adequate measure of the risk of subsequent events. From a clinical perspective, the routine measurement of platelet reactivity at the time of PCI is generally impractical because of the need to use specialized laboratory techniques such as light transmittance aggregometry (LTA).
  • LTA light transmittance aggregometry
  • an object of the present invention is to provide methods for measuring platelet reactivity of patients that have received (DES).
  • Another object of the present invention is to provide methods for identifying those PCI patients with DES who are at risk for stent thrombosis.
  • Yet another object of the present invention is to identify those patients with DES that have clopidogrel-induced platelet inhibition.
  • a blood sample is obtained from the patient.
  • the blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator.
  • the combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi.
  • a method for identifying a patient with DES at risk for stent thrombosis.
  • a blood sample is obtained from the patient.
  • the blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator.
  • the combination is incubated under conditions for agglutinating particles. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi. Platelet reactivity of the patient is measure.
  • a determination is made of a risk level of the patient for stent thrombosis.
  • a method for determining if a patient has clopidogrel-induced platelet inhibition.
  • a blood sample is obtained from the patient.
  • the blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator.
  • the combination is incubated under conditions for agglutinating particles.
  • the combination is incubated under conditions for agglutinating particles.
  • Platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi. Platelet reactivity of the patient is measured.
  • a determining is then made to determine if the patient has clopidogrel-induced platelet inhibition.
  • a method for measuring platelet reactivity of a patient that has a (DES).
  • An ADP platelet activator is added to a blood sample obtained from the patient.
  • One or more platelet inhibitors are provided to the sample.
  • At least one of the platelet inhibitors is Prostaglandin E1 (PGE1).
  • An alternate signal transduction pathway is produced in response to providing an ADP platelet activator and one or more platelet inhibitors.
  • a final concentration of ADP is about 2 to 35 ⁇ M and a final concentration of PGE1 is about 2 to 30 nM.
  • Platelet reactivity of the patient is measured in response to the final concentration of the ADP.
  • FIG. 1 illustrates the mean response of one individual.
  • FIG. 2 illustrates the mean response of five individuals.
  • FIG. 3 illustrates the extent of platelet aggregation from a blood sample treated with the antagonist of the present invention.
  • a composition of ADP and PGE1 is utilized as an activator in measuring inhibition of platelet aggregation by P2Y12 antagonists such as thienopyridines in whole blood samples.
  • P2Y12 antagonists such as thienopyridines in whole blood samples.
  • the aforementioned compositions may be employed to determine the effectiveness of anti-platelet therapy involving treatment of patients with a thienopyridine.
  • the above compositions may be employed in conjunction with particles coated with a GPIIb/IIIa receptor ligand and any other reagents necessary for conducting an assay for the efficacy of thienopyridines.
  • a lyophilized reagent composition may be used that comprises the aforementioned activator composition and particles.
  • a metered volume of a sample to be measured such as whole blood is mechanically mixed with the lyophilized reagent.
  • a change in light transmission is monitored and an index of platelet activity is calculated.
  • a whole blood sample is combined in a cuvette or a unitized cartridge with the aforementioned lyophilized reagent.
  • An apparatus may be employed for carrying out the assay.
  • the apparatus comprises a well for receiving the sample where the well contains the lyophilized reagent and other reagents for conducting the assay.
  • the additional reagents may be various buffers and/or lyophilization stabilizers.
  • the present invention is directed to a method for conducting an assay for platelet function activity on a whole blood sample.
  • the sample is one that has been affected by an adenosine-5-phosphate (ADP) antagonist.
  • the sample may be from a patient undergoing treatment with by an adenosine-5-phosphate (ADP) antagonist.
  • ADP adenosine-5-phosphate
  • a combination is provided in an assay medium where the combination comprises the sample and a composition of ADP and PGE1.
  • the final concentration of ADP is 2 to 35 ⁇ M, preferably, 15 to 20 ⁇ M and the final concentration of PGE1 is 2 to 30 nM, preferably 20 to 25 nM.
  • a reagent comprising particles coated with a compound that can result in the specific agglutination of platelets, i.e., the agglutination of platelets by the specific interaction between a receptor on the platelets and the compound on the particles.
  • a compound that can result in the specific agglutination of platelets, i.e., the agglutination of platelets by the specific interaction between a receptor on the platelets and the compound on the particles.
  • Such compounds include, by way of illustration and not limitation, antibodies to a platelet receptor and GPIIb/IIIa receptor ligands, which may be a small organic molecule, polypeptide, protein, monoclonal antibody or nucleic acid that binds, complexes or interacts with GPIIb/IIIa receptors on the platelet surface.
  • GPIIb/IIIa receptors on the surface of platelets bind, complex or otherwise interact with the GPIIb/IIIa receptor ligands on the particles.
  • Typical GPIIb/IIIa ligands include fibrinogen, monoclonal antibody 10E5 (Coller, et al., J. Clin. Invest. 72:325 (1983)), monoclonal antibody c7E3 (The EPIC Investigators, N.E.
  • the particles to which the compound is attached are at least about 0.1 microns and not more than about 20 microns. In one embodiment the particles are about 0.1 microns to about 10 microns. In another embodiment the particles are at least about 1 micron and less than about 8 microns.
  • the particles can be virtually any shape, but are generally spherical with uniform diameters.
  • the particle may have any density, but preferably of a density approximating water, generally from about 0.7 to about 1.5 g/ml.
  • the particles may or may not have a charge on the surface, either positive or negative, preferably negative.
  • the particles are functionalized or functionalizable so as to covalently bind or attach such members at their surface, either directly or indirectly.
  • the particles may be solid (e.g., comprised of organic and inorganic polymers or latex), oil droplets (e.g., hydrocarbon, fluorocarbon, silicon fluid), or vesicles (e.g., synthetic such as phospholipids or natural such as cells and organelles).
  • the solid particles are normally polymers, either addition or condensation polymers, which are readily dispersible in a liquid medium. Examples of suspendable particles are polymeric materials such as latex, lipid bilayers, oil droplets, cells and hydrogels.
  • Other particle compositions include polymers, such as nitrocellulose, cellulose acetate, poly(vinyl chloride), polyacrylamide, polyacrylate, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), nylon, poly(vinyl butyrate), polysaccharides such as dextrans and modified dextrans, etc.; either used by themselves or in conjunction with other materials.
  • the solid particles can be comprised of polystyrene, polyacrylamide, homopolymers and copolymers of derivatives of acrylate and methacrylate, particularly esters and amides, silicones and the like.
  • the compound is coated on the particles.
  • the compound is covalently attached to particles.
  • Such covalent attachment can be accomplished by well-known techniques, commonly available in the literature. See, for example, “Immobilized Enzymes,” Ichiro Chibata, Halsted Press, New York (1978) and Cuatrecasas, J. Biol. Chem., 245:3059 (1970).
  • the surface of the particle may be polyfunctional or be capable of being polyfunctionalized.
  • a wide variety of functional groups are available or can be incorporated. Functional groups include carboxylic acids, aldehydes, amino groups, cyano groups, ethylene groups, hydroxyl groups, mercapto groups and the like.
  • the manner of linking a wide variety of compounds to surfaces is well known and is amply illustrated in the literature (see above).
  • the attachment of the side member may be directly by a bond or indirectly through the intermediacy of a linking group.
  • the length of a linking group may vary widely, depending upon the nature of the side member and of the particle.
  • the ratio of molecules of compound to particle is controlled in the attachment of the molecules of compound to the particle.
  • the number of functionalized sites on the surface of the particle may be controlled by adjusting the number of such sites introduced on the surface of the particle.
  • the ratio of molecules of compound to particle may be controlled by adjusting the concentration of the compound in the reaction medium for the attachment, Other approaches will be suggested to one skilled in the art in view of the above teaching.
  • the particle reagent employed in the present invention may be treated with a sufficient amount of material to block areas of adsorption on the particles. Such materials will not affect the functioning of the particles for their intended purpose in the present invention.
  • the blocking materials include proteins such as bovine serum albumin, bovine gamma globulin, etc., polysaccharides such as dextran, etc., and the like.
  • particles are employed wherein the number of functionalized sites for attachment substantially reduce the adsorption area on the surface of the particles.
  • the particles usually comprise a label, either attached thereto or incorporated therein.
  • the label may be any moiety that may be used for the purpose of detection.
  • the label is often a member of a signal producing system.
  • the label is capable of being detected directly or indirectly.
  • the label can be isotopic or nonisotopic, usually non-isotopic, and can be a dye, fluorescent molecule, chemiluminescent molecule, a catalyst, such as an enzyme, a polynucleotide coding for a catalyst, promoter, coenzyme, enzyme substrate, radioactive group, a small organic molecule, amplifiable polynucleotide sequence, and so forth.
  • the particles contain one or more dyes that absorb in the infrared.
  • dyes include bacteriochlorin, bacteriochlorophytin, meropolymethine dyes, benzoannulenes, vinylogous porphorins, polymethine dyes, cyanines and merocyanines, and the like.
  • Specific dyes of interest are Copper(II)-tetra-tert-butyl-tetrakis(dimethylamino)-29H-31H-phthalocyanine and Vanadyl-tetra-tert-butyl-tetrakis(dimethylamino)-29H-31H-phthalocyanine.
  • the particular dye that is selected is one of convenience, availability, stability, compatibility with the particle and the like. These dyes may be incorporated directly into the particle itself, through polymerization or passive adsorption. The dyes may be loaded individually (i.e., sequentially) or in combination (i.e., simultaneously). Alternatively, the dyes may be linked to the bead in combination with the linking component, such that they do not leach from the surface. Irrespective of the loading method used, the conditions are such that the particle surface is unaffected with respect to the ability to agglutinate under appropriate conditions.
  • the dyes absorb light in the range of about 750 nm-900 nm, particularly in the range of about 750-850 nm. For samples with high levels of red blood cells, the light is at about 800 nm ⁇ 10 nm, which is the isobestic point for oxyhemoglobin and reduced hemoglobin.
  • the amount of dye employed with the particles varies with the extinction coefficient of the dye in the light range of interest, the required sensitivity of the assay, the size of the particles, the mode of binding of the dye to the particles, compatibility of the dye with the particle matrix, and the like. Usually, the amount of dye incorporated is in the range of about 1 to 20 weight percent, more usually 5 to 15 weight percent.
  • Dyes which find a particular use in the present invention are phthalocyanines.
  • transition metals and phthalocyanines are chemically very stable to light and heat. They are formed by condensation of opthalodinitriles in the presence of an appropriate metal.
  • metals used in the formation of the metalophthalocyanines besides the copper (Cu) and the Vanadium (V) are magnesium (Mg), zinc (Zn), and cobalt (Co).
  • carboxylated microparticles with a flat absorption maximum are employed. These microparticles are prepared by incorporating multiple dyes that have distinct absorption maximum close to 805 nm. This results in a flat maximum absorption spectrum across a broad range wavelength from 780-820 nm.
  • the sample may be any solution, synthetic or natural, to be analyzed where the sample has been subject to an effect from a P2Y12 antagonist, particularly, a thienopyridine, potentially in combination with aspirin.
  • sample includes biological tissue, including body fluids, from a host, and so forth.
  • the sample can be examined directly or may be pretreated, usually.
  • the present invention has particular application to samples that comprise platelets, including body fluids such as, for example, whole blood, platelet-containing blood fractions such as plasma, and the like. In one embodiment the invention has particular application to whole blood samples. The amount of the sample depends on the nature of the sample.
  • sample includes unprocessed samples directly from a patient or samples that have been pretreated and prepared in any convenient liquid medium, usually an aqueous medium (e.g., sodium citrate).
  • aqueous medium e.g., sodium citrate
  • the medium for conducting the assays in accordance with the present invention is an aqueous medium.
  • Other polar cosolvents may also be employed in the medium, usually oxygenated organic solvents of from 1-6, more usually from 1-4 carbon atoms, including alcohols, ethers and the like. Usually, such cosolvents are present in less than about 70 weight percent, more usually, in less than about 30 weight percent.
  • various ancillary materials are frequently employed in the method in accordance with the present invention.
  • buffers are normally present in the assay medium, as well as stabilizers for the assay medium and the assay components; surfactants, particularly non-ionic surfactants; binding enhancers, e.g., polyalkylene glycols; or the like.
  • the pH for the medium is usually in the range of about 2 to about 11, preferably, about 4 to about 9.
  • Various buffers may be used to achieve the desired pH and maintain the pH during the method.
  • Illustrative buffers include HEPES, borate, phosphate, carbonate, Tris, barbital, and the like.
  • the particular buffer employed is not critical to the method but one buffer may be preferred over others in certain circumstances. In some circumstances HEPES is preferred and is present at a concentration of about 0.05M to about 0.001M but generally at a concentration of about 0.01M.
  • the volume of assay medium is about 25 to about 500 microliters, usually about 75 to about 250 microliters.
  • the assays may be carried out in any suitable container.
  • the container is a cuvette or cartridge that is used with the instrument for carrying out the assay and measuring the assay results.
  • the reaction container usually contains the activation initiator in accordance with the present invention in dry lyophilized form together with other reagents such as the particle reagent and the like, stabilizers and so forth.
  • sample and particle reagent is incubated under conditions for agglutinating the particles.
  • Moderate temperatures are normally employed for carrying out the method.
  • the temperature may be constant or may vary. Usually, a constant temperature is employed during the reaction step.
  • the temperature employed is usually about 10 to about 80° C., more usually, about 15 to about 45° C., preferably, the temperature should be at least 25° C., more preferably in the range of about 30 to about 40° C., usually about 37° C.
  • the extent of agglutination of the particles is determined and is related to the presence and/or amount of the member in the sample.
  • the presence of agglutination may be determined visually by observing clumping of the particles, which would indicate agglutination.
  • the particles may be colored to aid in visualizing agglutination or clumping of the matrix.
  • the extent of agglutination may be measured spectrophotometrically, turbidimetrically, nephelometrically, etc., by observing the rate of change of optical density of the medium, and so forth.
  • an assay for platelet function activity is conducted on a whole blood sample from a patient undergoing treatment with a thienopyridine.
  • the sample is combined in a suitable container, e.g., reaction cuvette, with fibrinogen coated particles, and the composition of ADP and PGE1 to form an assay medium.
  • the particles of the particle reagent have one or more infrared dyes incorporated therein.
  • the combination is subjected to agglutination conditions.
  • the medium is irradiated with light in the infrared region.
  • the transmission of infrared light from the assay mixture is determined where the level of transmission is related to platelet function activity.
  • the agglutination medium is selected to have high absorption at ⁇ 800 nm.
  • the ratio between the agglutination medium absorption coefficient and whole blood absorption coefficient should preferably be greater than about 4:1 at 800 nm.
  • the absorption ratio for a particular assay is a function of both the absorption coefficient of the agglutination medium and the concentration of the agglutination medium in the assay sample.
  • the sample After the sample has been combined with the reagents, desirably it will be heated to a temperature above room temperature, but below that which would interfere with the assay, so as to insure that the temperature can be controlled without adversely affecting the assay result. Desirably, the temperature should be at least 250, preferably in the range of 30-40° C., more preferably about 37° C.
  • the reaction medium is usually gently agitated upon combining of the reagents with the sample and during the period of the reaction. Agitation is sufficient to achieve and maintain homogeneity in the assay samples.
  • the total time of the readings from the zero time (time of mixing) may range from about 10 sec. to 10 min., more usually about 30 sec. to 8 min., and preferably about 30 sec. to 3 min.
  • the data may be analyzed by any convenient means, particularly using an algorithm that can manipulate the data in relation to calibrators and/or controls.
  • the level of agglutination is an indication of the platelet function activity of the sample tested.
  • the level of agglutination may be compared against a standard of known platelet function activity. Usually, the result will be compared to a calibrator, which may be performed concomitantly or have been performed previously or may be provided as a standard curve.
  • the method of the present invention may be employed in conjunction with an assay for platelet count such as that described in U.S. patent application Ser. No. 09/177,884 filed Oct. 23, 1998 (the '884 application), the relevant disclosures of which are incorporated herein by reference.
  • the above assays preferably may be conducted in a device, which allows the reactions in accordance with the present invention to occur and which measures the results thereof.
  • the instrument should assess platelet function based upon the ability of activated platelets to bind fibrinogen. As activated platelets bind and agglutinate fibrinogen-coated particles, there is an increase in light transmittance.
  • an instrument to measure the result of the assay is one that can measure agglutination.
  • the instrument measures a change in optical signal due to agglutination.
  • Suitable instruments include, by way of illustration and not limitation a kinetic spectrophotometer, Ultegra System® instrument (commercially available from Accumetrics, San Diego, Calif. and employed for rapid platelet function activity measurements on normal samples), or the like.
  • the Ultegra® System instrument is a turbidometric based optical detection system, that measures platelet induced aggregation as an increase in light transmittance.
  • the system consists of an analyzer, disposable cartridge and controls.
  • the cartridge contains reagents based on microparticle agglutination technology.
  • the quality control system includes an electronic control, two levels of assayed “wet” controls (WQC), an in-cartridge humidity sensor, an in-packaging temperature indicator, and a test for concurrence of two assay channels.
  • the analyzer controls assay sequencing, establishes the assay temperature, controls the reagent-sample mixing for the required duration, determines the degree of platelet function, displays the result and performs self-diagnostics.
  • the test cartridge of the system contains a lyophilized preparation comprising particles with covalently attached GPIIb/IIIa receptor ligand, a composition of ADP and PGE1, and buffer.
  • the patient sample is usually citrated whole blood, which is automatically dispensed from the blood collection tube into the cartridge by the analyzer, with no blood handling required by the user.
  • the interaction is monitored by the infrared absorbency characteristics of the particles.
  • the agglutination of the particles is measured through the optical system of the UltegraTM analyzer.
  • the agglutination is detected as an increase in the transmission of infrared light through the sample.
  • the reaction kinetics are analyzed and translated into “P2Y12 Response Units”, PRU.
  • kits that includes in packaged combination a lyophilized preparation comprising particles with covalently attached fibrinogen, composition of ADP and PGE1, and buffer.
  • the lyophilized preparation may be present in a reaction container such as a cartridge used in the instrument of analysis.
  • the lyophilized preparation may be placed in the outer wells of the four-well cartridge used in the analyzer.
  • the kit may also include a sample collection container and/or a device for carrying out the present method.
  • the relative amounts of reagents may be varied widely to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of a determination.
  • the reagents can be placed in an air-tight package in order to maintain the activity of any reagents.
  • the package may be, for example, a bag, pouch, or the like fabricated from a material that is substantially non-permeable to moisture. Such materials include, by way of example and not limitation, plastic, aluminum foil, and the like.
  • the kit may also include an article for piercing a person's skin, disinfectant or sterilizing pads and so forth.
  • the kit may also include calibrators and standards.
  • the kit may also include one or more reagents for conducting an assay for platelet count.
  • the kit can include the reagents necessary for carrying out the assay of the present invention.
  • the kit includes a blood vial, a buffer that maintains the pH and salt concentration of the blood sample assessed within ranges suitable for platelet mediated agglutination of the solid surface and small polymeric beads coated with platelet GPIIb/IIIa receptor ligand.
  • the buffer can be in solution, or can consist solely of the buffering composition and salts to which a known amount of water is added to give the desired buffer solution.
  • the kit can also comprise an anticoagulant.
  • the buffer is HEPES; the anticoagulant is citrate; a GPIIb/IIIa receptor ligand is fibrinogen; small polymeric beads are polyacrylonitrile or carboxylated polystyrene in which a peptide GPIIb/IIIa receptor ligand, such as fibrinogen, is covalently bonded to the bead surface by means of a covalent bond between the N-terminus of the peptide and an N-hydroxysuccinimide or carboxylate group on the bead surface in a further embodiment, the kit additionally comprises a platelet activator, such as a composition of ADP and PGE1.
  • a platelet activator such as a composition of ADP and PGE1.
  • Dose response testing was performed withADP (Chronolog) and PGE1 (SIGMA) at 20 ⁇ M and 22 nM final concentrations respectively.
  • ADP was diluted in Hepes/Saline, pH 7.4 buffer to a final concentration of 200 ⁇ M prior to use on the aggregometer.
  • PGE1 was diluted in Hepes/Saline, pH 7.4 buffer to a final concentration of 220 nM prior to use on the aggregometer.
  • a P2Y12 receptor blocker was diluted in DMF to final concentrations of 1 mM, 2 mM and 5 mM.
  • P2Y12 compound Five microliters of the diluted P2Y12 compound were spiked into 5 mL whole blood. Samples were inverted and incubated for one hour at room temperature. The whole blood baseline sample did not receive any additive. Once incubation was complete, whole blood samples were spun at 1500 rpm for 15 minutes for platelet rich plasma (PRP) and 3500 rpm for 15 minutes for platelet poor plasma (PPP). Platelet count was adjusted to approximately 250,000/ ⁇ L for each sample using PPP.
  • PRP platelet rich plasma
  • PPP platelet poor plasma
  • the blank sample contained 450 ⁇ L PPP and 50 ⁇ L Hepes/Saline buffer. Fifty microliters of a composition of 200 ⁇ M ADP and 220 nM PGE1 was added to each PRP sample and tested for ten minutes on the aggregometer.
  • FIGS. 1 and 2 illustrates the mean response of one individual and five individuals, respectively.
  • methods are provided for measuring platelet reactivity of patients following PCI receiving DES. In one embodiment, methods are provided for identifying those patients with DES at risk for stent thrombosis. In another embodiment, methods are provided for identifying those patients with DES that have clopidogrel-induced platelet inhibition.
  • PCI patients with DES can benefit with increased dosing of clopidogrel should be considered in patients >100 kg.
  • EXPLAIN Point-of-care testing of platelet function at the time of PCI may identify patients at high-risk for stent thrombosis over 30-day follow-up. At-risk patients can benefit from increased clopidogrel dosing regimens or alternative anti-platelet strategies (e.g., prasugrel).
  • the patients selected had at least one of the following, at least one lesion ⁇ 50% diameter stenosis requiring PCI, a reference vessel diameter between 2.25 and 4.0 mm, target lesion located within a native coronary artery or bypass graft that was either de novo or restenotic and no known allergy to aspirin, clopidogrel, or any component of an DES.
  • the percentage inhibition was considered to be zero.
  • the percentage inhibition reported by the device using the internal reference channel was used.
  • High post-treatment reactivity the highest quartile of absolute PRU while on clopidogrel (on chronic therapy or 12 hours after loading dose).
  • Clopidogrel non-responsiveness the lowest quartile of percent inhibition of platelet function (relative change in platelet reactivity after clopidogrel compared to the patient's baseline or the reference channel).
  • the clinical endpoints measured were death, MI (non-Q-wave and Qwave) and stent thrombosis.
  • Peri-procedural non-Q wave myocardial infarction (MI) was defined as CK-MB>3 times the upper limit of normal in the absence of pathological Q waves.
  • MI during the 30-day follow-up period was defined as any elevation in cardiac enzymes considered due to ischemia by the clinical events committee.
  • Stent thrombosis was defined as any of the following, angiographic demonstration of stent closure or thrombus, unexplained sudden death, MI without concomitant documentation of a patient stent.
  • Acute thrombosis was defined as thrombosis occurring within 24 hours of the PCI, and sub-acute thrombosis as occurring between 24 hours and the 30-day follow-up.
  • SPSS Statistical Package for the Social Sciences, 12.0 for PC, SPSS Inc., Chicago, Ill.
  • the following variables were tested and entered into the multivariate analysis if the p value was >0.10 on univariate analysis, age, gender, weight, body mass index (BMI) ⁇ 30 kg/m2, history of diabetes, insulin resistance, history of CHF, history of MI, history of HTN, current smoking, renal insufficiency (creatinine ⁇ 1.5), EF ⁇ 40%, presentation with MI, presentation with angina, bivalirudin use, and prior use of aspirin, beta-blockers or atorvastatin.
  • BMI body mass index
  • N 280 Mean age (yrs) 68 ⁇ 11 Male gender 213 (76%) Diabetes Mellitus 75 (27%) History of CHF 28 (10%) Previous MI 82 (29%) Current smoker 28 (10%) Weight (kg) 89.5 ⁇ 24.9 Body Mass Index (kg/m2) 29.8 ⁇ 7.8 Medical Therapy Chronic aspirin 242 (86%) Chronic clopidogrel 101 (36%) Beta-blocker 171 (61%)
  • the indications for a procedure were determined by one of the following, stable angina or ischemia in 261 patients (93%), unstable angina in 13 patients (4.8%), acute MI in 6 patients (2.2%).
  • Stent thrombosis was found in a number of patients. All patients were taking dual antiplatelet therapy at the time of the thrombosis.
  • Patient No. 1 had acute thrombosis 80 minutes after PCI, and was on clopidogrel at the time of the procedure. The percentage of inhibition for patient No. 1 was 0%.
  • Patient No. 2 had sub-acute thrombosis 6 days following PCI and was on clopidogrel at the time of procedure. The percentage of inhibition for patient No. 2 was 0%.
  • Patient No. 3 had sub-acute thrombosis 34 days following-PCI, was clopidogrel näive and loaded with 600-mg at the time of the procedure. The percentage inhibition for patient No. 3 was 0%.
  • Patient No. 1 had acute thrombosis 80 minutes after PCI, and was on clopidogrel at the time of the procedure. The percentage of inhibition for patient No. 1 was 0%.
  • Patient No. 2 had sub-acute thro
  • one quarter of patients undergoing PCI had clopidogrel-induced platelet inhibition, defined as ⁇ 10% as measured by a point-of-care assay.
  • Patients presented with MI had heavier weight, and beta-blocker use was independently associated with clopidogrel non-responsiveness.
  • Clopidogrel non-response was significantly associated with stent thrombosis over a 30 day follow-up, particularly in the setting of high absolute post-treatment reactivity.
  • dosing of clopidogrel should be increased for patients greater than 100 kg.
  • point-of-care testing of platelet function at the time of PCI, can be used to identify patients at high-risk for stent thrombosis over a thirty day follow-up. At-risk patients can benefit from increased clopidogrel dosing regimens or alternative anti-platelet strategies, including but not limited to prasugrel and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US11/742,684 2003-07-08 2007-05-01 Methods for measuring platelet reactivity of patients that have received drug eluting stents Abandoned US20070243632A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US11/742,684 US20070243632A1 (en) 2003-07-08 2007-05-01 Methods for measuring platelet reactivity of patients that have received drug eluting stents
KR1020097024975A KR20100017510A (ko) 2007-05-01 2008-05-01 약물 용출 스텐트로 처치된 개체의 혈소판 반응성을 측정하는 방법
PCT/US2008/062297 WO2008137600A1 (en) 2007-05-01 2008-05-01 Methods for measuring platelet reactivity of individuals treated with drug eluting stents
US12/598,581 US9506938B2 (en) 2003-07-08 2008-05-01 Methods for measuring platelet reactivity of individuals treated with drug eluting stents
CN200880022878A CN101688871A (zh) 2007-05-01 2008-05-01 测量用药物洗脱支架治疗的个体的血小板反应性的方法
EP08754988A EP2145192A1 (en) 2007-05-01 2008-05-01 Methods for measuring platelet reactivity of individuals treated with drug eluting stents
JP2010506656A JP5687055B2 (ja) 2007-05-01 2008-05-01 薬剤溶出性ステントで処理された個体の血小板反応性を評価する方法
US12/943,413 US9341637B2 (en) 2003-07-08 2010-11-10 Controlled platelet activation to monitor therapy of ADP antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48570303P 2003-07-08 2003-07-08
US10/886,155 US7790362B2 (en) 2003-07-08 2004-07-06 Controlled platelet activation to monitor therapy of ADP antagonists
US11/742,684 US20070243632A1 (en) 2003-07-08 2007-05-01 Methods for measuring platelet reactivity of patients that have received drug eluting stents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/886,155 Continuation-In-Part US7790362B2 (en) 2003-07-08 2004-07-06 Controlled platelet activation to monitor therapy of ADP antagonists

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/598,581 Continuation US9506938B2 (en) 2003-07-08 2008-05-01 Methods for measuring platelet reactivity of individuals treated with drug eluting stents
PCT/US2008/062297 Continuation WO2008137600A1 (en) 2003-07-08 2008-05-01 Methods for measuring platelet reactivity of individuals treated with drug eluting stents
US59858110A Continuation 2003-07-08 2010-03-30

Publications (1)

Publication Number Publication Date
US20070243632A1 true US20070243632A1 (en) 2007-10-18

Family

ID=39615637

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/742,684 Abandoned US20070243632A1 (en) 2003-07-08 2007-05-01 Methods for measuring platelet reactivity of patients that have received drug eluting stents
US12/598,581 Active 2030-02-25 US9506938B2 (en) 2003-07-08 2008-05-01 Methods for measuring platelet reactivity of individuals treated with drug eluting stents

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/598,581 Active 2030-02-25 US9506938B2 (en) 2003-07-08 2008-05-01 Methods for measuring platelet reactivity of individuals treated with drug eluting stents

Country Status (6)

Country Link
US (2) US20070243632A1 (enExample)
EP (1) EP2145192A1 (enExample)
JP (1) JP5687055B2 (enExample)
KR (1) KR20100017510A (enExample)
CN (1) CN101688871A (enExample)
WO (1) WO2008137600A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031616A1 (en) * 2003-07-08 2005-02-10 Coller Barry S. Controlled platelet activation to monitor therapy of ADP antagonists
US20060246528A1 (en) * 2005-04-27 2006-11-02 Lisa Swaim Method and system for absolute platelet percent aggregation determination
US20080299587A1 (en) * 2007-05-03 2008-12-04 Dennis Durbin Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists
EP2508892A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
WO2016135335A1 (en) * 2015-02-27 2016-09-01 Randox Laboratories Ltd Prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention
US9506938B2 (en) 2003-07-08 2016-11-29 Accumetrics, Inc. Methods for measuring platelet reactivity of individuals treated with drug eluting stents
US9915671B2 (en) 2008-12-23 2018-03-13 C A Casyso Ag Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US20220211901A1 (en) * 2021-01-07 2022-07-07 Baxter International Inc. Thrombin-free hemostatic materials, methods of manufacture, and uses thereof
US12031993B2 (en) 2014-09-29 2024-07-09 C A Casyso Gmbh Blood testing system and method

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371284A1 (en) * 2010-03-24 2011-10-05 C A Casyso AG Method and apparatus for determining at least one evaluation parameter of a blood sample
RU2442167C1 (ru) * 2010-07-21 2012-02-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ оценки эффективности действия антиагрегантных препаратов, влияющих на метаболизм арахидоновой кислоты путем ингибирования циклооксигеназы-1 как в отдельности, так и совместно с антагонистом рецептора адф p2y12 на тромбоцитарных мембранах, на состояния тромбоцитов крови пациента, принимающего антиагрегантные препараты указанной группы
JP5768422B2 (ja) * 2011-03-17 2015-08-26 ソニー株式会社 血液凝固系解析方法および血液凝固系解析装置
DE102014112270B3 (de) * 2014-08-27 2015-04-23 Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V. Verfahren zur Messung der Thrombozytenfunktion
MX2017012732A (es) * 2015-04-08 2017-11-30 Koninklijke Philips Nv Sistema para analisis automatizado de valores de laboratorio y notificacion de riesgo en unidad de cuidados intensivos.
CN105203752A (zh) * 2015-11-05 2015-12-30 上海中山医疗科技发展公司 一种磁性血小板吸附颗粒及其制备方法
CN105717263B (zh) * 2016-03-04 2018-01-26 北京乐普医疗科技有限责任公司 一种检测噻吩并吡啶类抗血小板药物疗效的试剂卡及其使用方法和应用
WO2023238136A1 (en) * 2022-06-08 2023-12-14 Ichilov Tech Ltd. Methods of assessing platelet aggregation

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518057A (en) * 1966-04-22 1970-06-30 Huron Road Hospital Method and apparatus for thrombus formation time determinations
US3694161A (en) * 1971-04-14 1972-09-26 Armour Pharma Method for measuring platelet aggregation
US4051236A (en) * 1973-02-15 1977-09-27 E. R. Squibb & Sons, Inc. Inhibition of blood platelet aggregation
US4066360A (en) * 1974-02-21 1978-01-03 B. Braun Melsungen Aktiengesellschaft Device for measuring and recording spontaneous blood platelet aggregation in platelet-rich citrated plasma
US4820836A (en) * 1986-03-31 1989-04-11 Shionogi & Co., Ltd. Prostacyclin (PGI2) analogues
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5066592A (en) * 1988-03-08 1991-11-19 Temple University Of The Commonwealth System Of Higher Education Trigramin - a platelet aggregation inhibiting polypeptide
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5455228A (en) * 1993-07-02 1995-10-03 The Research Foundation Of State University Of New York Peptidase resistant thrombin receptor peptide ligand
US5763199A (en) * 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
USD409758S (en) * 1998-01-14 1999-05-11 Accumetrics Sample cartridge
US5922551A (en) * 1997-03-20 1999-07-13 Accumetrics, Inc. Agglutrimetric platelet binding assays in blood
US5989578A (en) * 1996-02-19 1999-11-23 Sanofi Associations of active principles containing clopidogrel and an antithrombotic agent
US6016712A (en) * 1997-09-18 2000-01-25 Accumetrics Device for receiving and processing a sample
US6043871A (en) * 1997-03-03 2000-03-28 Brigham Young University System and method for measuring blood platelet function
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US6210904B1 (en) * 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
US6555064B2 (en) * 1996-04-30 2003-04-29 Medtronic, Inc. Method for determining platelet inhibitor response
US6645987B2 (en) * 2000-06-15 2003-11-11 Schering Corporation Nor-seco himbacine derivatives useful as thrombin receptor antagonists
US20050031616A1 (en) * 2003-07-08 2005-02-10 Coller Barry S. Controlled platelet activation to monitor therapy of ADP antagonists
US7037920B2 (en) * 2001-10-18 2006-05-02 Schering Corporation Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
US20060246528A1 (en) * 2005-04-27 2006-11-02 Lisa Swaim Method and system for absolute platelet percent aggregation determination
US20060246527A1 (en) * 2005-04-28 2006-11-02 Mchugh Sean Method and system for stabilization of arachidonic acid for use in platelet function assay
US7244730B2 (en) * 2001-04-19 2007-07-17 Eisai Co., Ltd 2-iminopyrrolidine derivatives
US20080299587A1 (en) * 2007-05-03 2008-12-04 Dennis Durbin Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US409758A (en) * 1889-08-27 Velocipede
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
JPS5697226A (en) 1979-12-28 1981-08-05 Mitsubishi Chem Ind Ltd Blood platelet coagulation inhibitor
US4622293A (en) 1983-07-05 1986-11-11 Miles Laboratories, Inc. Iodothyronine immunoassays employing HMS as TBP blocking agent
US4717654A (en) 1984-06-19 1988-01-05 Akzo N.V. Process for solid phase platelet antibody assay
US4619904A (en) 1984-10-29 1986-10-28 General Electric Company Agglutinating immunoassay using protein-coated liquid droplets
US4634681A (en) 1984-10-29 1987-01-06 General Electric Company Diagnostic method of determining the presence or absence of select proteins in a liquid sample
US4948961A (en) 1985-08-05 1990-08-14 Biotrack, Inc. Capillary flow device
DE3717337A1 (de) * 1987-05-22 1988-12-15 Hoechst Ag Verfahren zum nachweis der antiaggregatorischen wirkung von vasoaktiven stoffen, speziell von phosphodiesterase- und/oder cyclooxygenase-hemmern
US5114842A (en) 1987-07-08 1992-05-19 The Scripps Research Institute Peptides and antibodies that inhibit platelet adhesion
BR9106391A (pt) 1990-04-30 1993-04-27 Isis Pharmaceuticals Inc Oligonucleotideo ou analogo de oligonucleotideo,processo para modular o metaboslismo do acido araquidonico em um animal,e,processo para tratar um anumal suspeito de ter uma doenca que e modulada por mudancas na sintese ou no metabolismo do acido arquidonico
US5246832A (en) 1990-06-20 1993-09-21 University Of Massachusetts Medical Center Platelet analysis in whole blood
US5196309A (en) 1990-11-15 1993-03-23 The Scripps Research Institute Characterization of platelet aggregation disorders
US5688768A (en) 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US5266462A (en) 1992-06-03 1993-11-30 Baxter Diagnostics Inc. Measurement of platelet activities
US5427913A (en) 1992-12-03 1995-06-27 Alberta Cancer Board Methods for determining platelet function
AU7112794A (en) 1993-06-18 1995-01-17 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
IL106330A (en) 1993-07-14 1998-01-04 Univ Ramot Method and instrument for determining the activity of their plaques in the initial coagulation system
US5486361A (en) 1993-10-25 1996-01-23 The United States Of America As Represented By The Department Of Health And Human Services Hybridomas and monoclonal antibodies that speifically bind to GPIB on platelets and inhibit the binding of thrombin to platelets
DE4344919A1 (de) 1993-12-30 1995-07-06 Behringwerke Ag Verfahren zur Bestimmung der Thrombozytenaggregation
WO1995027209A1 (en) 1994-03-31 1995-10-12 The Trustees Of The University Of Pennsylvania Method and kit for detection of thrombin receptor activation of platelets and other cells
ATE186121T1 (de) 1994-07-23 1999-11-15 Roche Diagnostics Gmbh Verfahren zur bestimmung des präthrombotischen status
US5952006A (en) 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US5753517A (en) 1996-03-29 1998-05-19 University Of British Columbia Quantitative immunochromatographic assays
US6010911A (en) 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
DE69825173T2 (de) 1997-10-30 2005-08-25 Morishita Jintan Co. Ltd. Doppelschichtige kapsel von ungesättigten fettsäuren oder deren derivate und verfahren zu deren herstellung
JP2002504369A (ja) 1998-02-27 2002-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ活性化レセプター４およびその使用。
EP0964046B1 (en) 1998-06-03 2003-07-30 Mitsubishi Gas Chemical Company, Inc. Oxygen absorbing composition, oxygen absorbing resin and preserving method
US6093370A (en) 1998-06-11 2000-07-25 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
CN1189166C (zh) 1998-09-11 2005-02-16 伊来克萨斯独资有限公司 Fc受体调节剂及其应用
WO2000025140A1 (en) 1998-10-23 2000-05-04 Accumetrics, Inc. Method for determining platelet count
WO2000073792A1 (en) 1999-05-28 2000-12-07 Sendx Medical, Inc. Control for methods for determining platelet count and platelet function
EP1216037A2 (en) * 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US6994983B2 (en) * 1999-10-25 2006-02-07 Esoterix, Inc. Coagulation Kits for determination of thromboxane B2 metabolite and optimizing aspirin dosage
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US20020077693A1 (en) * 2000-12-19 2002-06-20 Barclay Bruce J. Covered, coiled drug delivery stent and method
WO2002026109A2 (en) 2000-09-29 2002-04-04 Endovasc Ltd., Inc. Resorbable prosthesis for medical treatment
AU2002210982A1 (en) 2000-11-01 2002-05-15 Yamanouchi Pharmaceutical Co..Ltd. Method of screening antiplatelet
US6841354B2 (en) 2000-12-21 2005-01-11 Philadelphia, Health & Education Corporation Screening assay for anti-thrombotic/anti-platelet activity
CA2450236A1 (en) 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
US6833536B2 (en) 2002-05-22 2004-12-21 Applera Corporation Non-contact radiant heating and temperature sensing device for a chemical reaction chamber
FR2840409B1 (fr) * 2002-05-28 2004-08-27 Dev Des Antigenes Combinatoire Dispositif de presentation de peptides ou de proteines, son procede de preparation et ses utilisations
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
AU2003277398A1 (en) 2002-10-15 2004-05-04 The University Of Tennessee Research Foundation Methods for assessment of platelet aggregation
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
CA2697635C (en) 2007-11-30 2016-06-28 Corbett Research Pty Ltd Thermal cycling device

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518057A (en) * 1966-04-22 1970-06-30 Huron Road Hospital Method and apparatus for thrombus formation time determinations
US3694161A (en) * 1971-04-14 1972-09-26 Armour Pharma Method for measuring platelet aggregation
US4051236A (en) * 1973-02-15 1977-09-27 E. R. Squibb & Sons, Inc. Inhibition of blood platelet aggregation
US4066360A (en) * 1974-02-21 1978-01-03 B. Braun Melsungen Aktiengesellschaft Device for measuring and recording spontaneous blood platelet aggregation in platelet-rich citrated plasma
US4820836A (en) * 1986-03-31 1989-04-11 Shionogi & Co., Ltd. Prostacyclin (PGI2) analogues
US5066592A (en) * 1988-03-08 1991-11-19 Temple University Of The Commonwealth System Of Higher Education Trigramin - a platelet aggregation inhibiting polypeptide
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5455228A (en) * 1993-07-02 1995-10-03 The Research Foundation Of State University Of New York Peptidase resistant thrombin receptor peptide ligand
US5763199A (en) * 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
US5854005A (en) * 1994-09-29 1998-12-29 Mount Sinai School Of Medicine Platelet blockade assay
US5989578A (en) * 1996-02-19 1999-11-23 Sanofi Associations of active principles containing clopidogrel and an antithrombotic agent
US6555064B2 (en) * 1996-04-30 2003-04-29 Medtronic, Inc. Method for determining platelet inhibitor response
US6043871A (en) * 1997-03-03 2000-03-28 Brigham Young University System and method for measuring blood platelet function
US5922551A (en) * 1997-03-20 1999-07-13 Accumetrics, Inc. Agglutrimetric platelet binding assays in blood
US6016712A (en) * 1997-09-18 2000-01-25 Accumetrics Device for receiving and processing a sample
US6210904B1 (en) * 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US6326380B1 (en) * 1997-11-25 2001-12-04 Schering Corporation Thrombin receptor antagonists
USD409758S (en) * 1998-01-14 1999-05-11 Accumetrics Sample cartridge
US6894065B2 (en) * 2000-06-15 2005-05-17 Schering Corporation Thrombin receptor antagonists
US6645987B2 (en) * 2000-06-15 2003-11-11 Schering Corporation Nor-seco himbacine derivatives useful as thrombin receptor antagonists
US7244730B2 (en) * 2001-04-19 2007-07-17 Eisai Co., Ltd 2-iminopyrrolidine derivatives
US7304083B2 (en) * 2001-04-19 2007-12-04 Eisai R&D Management Co., Ltd. 2-iminoimidazole derivatives (2)
US7037920B2 (en) * 2001-10-18 2006-05-02 Schering Corporation Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
US20050031616A1 (en) * 2003-07-08 2005-02-10 Coller Barry S. Controlled platelet activation to monitor therapy of ADP antagonists
US20060246528A1 (en) * 2005-04-27 2006-11-02 Lisa Swaim Method and system for absolute platelet percent aggregation determination
US20060246527A1 (en) * 2005-04-28 2006-11-02 Mchugh Sean Method and system for stabilization of arachidonic acid for use in platelet function assay
US7205115B2 (en) * 2005-04-28 2007-04-17 Accumetrics, Inc. Method and system for stabilization of arachidonic acid for use in platelet function assay
US20080299587A1 (en) * 2007-05-03 2008-12-04 Dennis Durbin Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9341637B2 (en) 2003-07-08 2016-05-17 Accumetrics Inc. Controlled platelet activation to monitor therapy of ADP antagonists
US7790362B2 (en) 2003-07-08 2010-09-07 Accumetrics, Inc. Controlled platelet activation to monitor therapy of ADP antagonists
US20110081657A1 (en) * 2003-07-08 2011-04-07 Accumetrics, Inc. Controlled platelet activation to monitor therapy of adp antagonists
US20050031616A1 (en) * 2003-07-08 2005-02-10 Coller Barry S. Controlled platelet activation to monitor therapy of ADP antagonists
US9506938B2 (en) 2003-07-08 2016-11-29 Accumetrics, Inc. Methods for measuring platelet reactivity of individuals treated with drug eluting stents
US8574828B2 (en) 2003-07-08 2013-11-05 Accumetrics, Inc. Controlled platelet activation to monitor therapy of ADP antagonists
US20060246528A1 (en) * 2005-04-27 2006-11-02 Lisa Swaim Method and system for absolute platelet percent aggregation determination
US7595169B2 (en) 2005-04-27 2009-09-29 Accumetrics, Inc. Method for determining percent platelet aggregation
US20080299587A1 (en) * 2007-05-03 2008-12-04 Dennis Durbin Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists
US11360106B2 (en) 2008-12-23 2022-06-14 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US11061038B2 (en) 2008-12-23 2021-07-13 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US12111326B2 (en) 2008-12-23 2024-10-08 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US12105103B2 (en) 2008-12-23 2024-10-01 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US9915671B2 (en) 2008-12-23 2018-03-13 C A Casyso Ag Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US10746750B2 (en) 2008-12-23 2020-08-18 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US10996230B2 (en) 2008-12-23 2021-05-04 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US11892459B2 (en) 2008-12-23 2024-02-06 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US11131680B2 (en) 2008-12-23 2021-09-28 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US11879899B2 (en) 2008-12-23 2024-01-23 C A Casyso Gmbh Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
EP2508892A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
US8741873B2 (en) 2011-04-04 2014-06-03 Siemens Healthcare Diagnostics Products Gmbh Controls and kit for thrombocyte activity tests
EP2508893A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
US12031993B2 (en) 2014-09-29 2024-07-09 C A Casyso Gmbh Blood testing system and method
WO2016135335A1 (en) * 2015-02-27 2016-09-01 Randox Laboratories Ltd Prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention
US20220211901A1 (en) * 2021-01-07 2022-07-07 Baxter International Inc. Thrombin-free hemostatic materials, methods of manufacture, and uses thereof

Also Published As

Publication number Publication date
US20100184084A1 (en) 2010-07-22
JP5687055B2 (ja) 2015-03-18
US9506938B2 (en) 2016-11-29
WO2008137600A1 (en) 2008-11-13
KR20100017510A (ko) 2010-02-16
JP2010526300A (ja) 2010-07-29
EP2145192A1 (en) 2010-01-20
CN101688871A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
US20070243632A1 (en) Methods for measuring platelet reactivity of patients that have received drug eluting stents
US8574828B2 (en) Controlled platelet activation to monitor therapy of ADP antagonists
EP2153235B1 (en) Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists
Yardumian et al. Laboratory investigation of platelet function: a review of methodology.
Hechler et al. Platelet preparation for function testing in the laboratory and clinic: Historical and practical aspects
US9789166B2 (en) Assessment of cardiac health and thrombotic risk in a patient
McGlasson et al. Whole blood platelet aggregometry and platelet function testing
US7205115B2 (en) Method and system for stabilization of arachidonic acid for use in platelet function assay
WO2002059623A2 (en) Methods for determining platelet activity with antiplatelet compositions
HK1142680A (en) Methods for measuring platelet reactivity of individuals treated with drug eluting stents
HK1158311A (en) Method and system for stabilization of arachidonic acid for use in platelet function assay

Legal Events

Date Code Title Description
AS Assignment

Owner name: ACCUMETRICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLER, BARRY S.;DURBIN, DENNIS;REEL/FRAME:019493/0403;SIGNING DATES FROM 20070611 TO 20070613

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SILICON VALLEY BANK, CALIFORNIA

Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT (REVOLVING LOAN);ASSIGNOR:ACCUMETRICS, INC.;REEL/FRAME:029621/0445

Effective date: 20121228

Owner name: SILICON VALLEY BANK, CALIFORNIA

Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT (TERM LOAN);ASSIGNOR:ACCUMETRICS, INC.;REEL/FRAME:029621/0651

Effective date: 20121228

Owner name: HORIZON TECHNOLOGY FINANCE CORPORATION, CONNECTICU

Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT (TERM LOAN);ASSIGNOR:ACCUMETRICS, INC.;REEL/FRAME:029621/0651

Effective date: 20121228

AS Assignment

Owner name: ACCUMETRICS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:031112/0731

Effective date: 20130829

Owner name: ACCUMETRICS, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:HORIZON TECHNOLOGY FINANCE CORPORATION;SILICON VALLEY BANK;REEL/FRAME:031112/0835

Effective date: 20130829

AS Assignment

Owner name: COMERICA BANK, CALIFORNIA

Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:ACCUMETRICS, INC.;REEL/FRAME:031645/0678

Effective date: 20131112